IM 카나비스IMCC 주가

"Marijuana Components Have 'Consistent' Anti-Tumor Effects In Glioblastoma And Other Cancers, Scientific Review Shows" - Marijuana Moment

https://www.marijuanamoment.net/marijuana-components-have-consistent-anti-tumor-effec

12 Health Care Stocks Moving In Thursday's After-Market Session

IM Cannabis Corp. Announces First Quarter 2026 Financial Results

IM Cannabis Corp. ("IMC" or the "Company") (Nasdaq: IMCC), a medical cannabis company with operations in Israel and Germany, today announced its financial results for the first quarter ended March 31, 2026. All amounts were reported in Canadian dollars, unless otherwise stated.

IM Cannabis Q1 EPS $(0.28) Down From $0.06 YoY, Sales $6.343M Down From $8.708M YoY

IM Cannabis (NASDAQ:IMCC) reported quarterly losses of $(0.28) per share. This is a 566.67 percent decrease over earnings of $0.06 per share from the same period last year. The company reported $6.343 million in sales

[6-K] 6-K — 6-K

Get insights into the top gainers and losers of Friday's after-hours session.

After the conclusion of the US market's regular session on Friday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

IM Cannabis Raised US$550,000 of Gross Proceeds in Convertible Note Financings

IM Cannabis Corp. ("IMC" or the "Company") (Nasdaq: IMCC), a medical cannabis company with operations in Israel and Germany, today announced the closing of a US$300,000 convertible note financing in a private placement with an institutional investor, bringing the total gross proceeds raised in recent similar financings to US$550,000.

[6-K] 6-K — 6-K

[6-K] 6-K — 6-K

[6-K] 6-K — 6-K